Peptonic signs license agreement with Prima Lab regarding self-test for urinary tract infections

PEPTONIC Medical AB announces that the company has signed a license agreement with Swiss medical technology company Prima Lab SA regarding self-tests for urinary tract infections for sale in Sweden.

The agreement means that Peptonic gets the right to sell Prima Lab’s self-test for urinary tract infections under its own brand VagiVital© in Sweden, with a planned launch at the end of 2023.

“Urinary tract infections affect 40% of all women of all ages at some point in their lives, with many experiencing recurrent infections. Adding another high-quality self-test to the reference market Sweden will be another valuable step in building a leading portfolio of clinically proven self-care products consistent with the principle of diagnose, treat and prevent”, says Erik Sundquist, CEO of Peptonic.

Prima Lab is a Swiss medical technology company with a specific focus on self-tests for women’s health. The company conducts its own research and development and sells its products in more than thirty countries around the world. Prima Lab’s self-test for urinary tract infections has a high level of precision as it measures on four parameters – blood, protein, leukocytes and nitrites – unlike most other products that measure only two or three parameters.

Prima Lab is already a strategic partner to Peptonic as Prima distributes Peptonics patented test for amniocentesis exclusively in a number of selected markets in Europe.

“To deepen the collaboration with Prima Lab, which is a leading player in self-tests for women’s health, we see as a very valuable step as we continue to build our portfolio”, says Erik Sundquist.

“Peptonic is a growing and important player in women’s health. Accordingly, we see the introduction of our self-test for urinary tract infections on the Swedish market as very valuable for our continued expansion”, says Prima Lab’s CEO and founder Federico Roveda.

About Prima Lab

Prima Lab’s vision is to create a world where diseases are identified before medical treatments are needed and thus work preventively. It is done by focusing on clinically proven self-tests in a number of therapeutic areas. The company was founded in 2014 and has since then grown very rapidly and now has over 200 products sold in more than 30 countries. The head office is located in Balerna, Switzerland, where they conduct development, production and sales. For more information see

About Peptonic Medical AB

Peptonic is a Swedish innovative biomedical company that conducts research, development and sales of medical treatments and lifestyle products in the field of women’s health. Peptonic has divided its operations into two business areas: “Medical Consumer” and “Lifestyle Consumer”. The business area “Medical Consumer” is based on clinically proven intimate self-care and constitutes the company’s main focus and is sold under the VagiVital brand. The “Lifestyle Consumer” business area consists of lifestyle products with a focus on sustainable menstrual products and is sold under the Lunette brand. The company was founded in 2009 and the stock has been traded since 2014 on Spotlight ( in Stockholm. More information about Peptonic Medical is available on